文献速递瓣膜外科

经心尖导管二尖瓣植入术治疗原生二尖瓣狭窄:球囊扩张瓣膜的早期经验

Transapical Mitral Valve Implantation for Native Mitral Valve Stenosis Using a Balloon-Expandable Prosthesis.
PubMed 文献 · Ann Thorac Surg · 2017-07-29

该单中心早期研究纳入6例因严重瓣环钙化及合并症被拒绝常规手术的重度原生二尖瓣狭窄患者,经心尖或经左房途径植入SAPIEN 3瓣膜作为补救治疗。初始植入成功率100%,术后平均跨瓣压差由11.1 mmHg降至4.2 mmHg,30天死亡1例(17%),无院内卒中。

要点

  • 对严重瓣环钙化、外科手术高危的原生二尖瓣狭窄,经导管植入SAPIEN 3瓣膜可作为补救方案。
  • 术后平均跨瓣压差由11.1±2.1 mmHg降至4.2±0.6 mmHg,有效瓣口面积由0.9±0.12 cm²增至2.8±0.4 cm²。
  • 早期瓣膜移位需行瓣中瓣1例,术后无残余反流4例、轻度反流2例。

核心结论

  • 使用SAPIEN 3主动脉瓣膜行经导管二尖瓣植入术,对严重瓣环钙化的不可手术原生二尖瓣狭窄患者可行,可作为合理的补救选择。
  • 该特殊人群仍存在若干需考虑的局限性。

研究设计与样本

  • 单中心早期经验,2014年1月至2015年6月筛查11例,其中6例重度原生二尖瓣狭窄患者接受经导管二尖瓣置换作为补救手术。
  • 患者平均年龄77.4±6.3岁,66%为男性,平均logistic EuroScore为31.4%±8.3%,均因严重瓣环钙化和广泛合并症被拒绝常规外科手术。
  • 全部使用29 mm Edwards SAPIEN 3瓣膜;5例经心尖途径,1例经胸骨正中切开经左房途径同期行主动脉瓣置换。

主要发现

  • 初始植入成功率为100%。
  • 因早期瓣膜移位,1例需行瓣中瓣手术。
  • 术后超声心动图显示4例(66%)无残余二尖瓣反流,2例(34%)为轻度反流。
  • 平均跨瓣压差降至4.2±0.6 mmHg,平均有效瓣口面积为2.8±0.4 cm²。
  • 住院期间无患者发生卒中,30天死亡1例(17%),原因为肺炎。

关键数值与推荐

  • 术前平均跨瓣压差11.1±2.1 mmHg,平均有效瓣口面积0.9±0.12 cm²。
  • 术后平均跨瓣压差4.2±0.6 mmHg,平均有效瓣口面积2.8±0.4 cm²。
  • 全部病例使用29 mm Edwards SAPIEN 3瓣膜。

临床怎么用

  • 对于严重瓣环钙化且外科手术高危或禁忌的重度原生二尖瓣狭窄患者,可考虑经导管二尖瓣植入术作为补救治疗。
  • 可使用SAPIEN 3主动脉瓣膜经心尖途径植入,需警惕早期瓣膜移位并准备瓣中瓣补救。

局限性

  • 样本量小(6例),为单中心早期经验。
  • 原文指出该特殊患者人群仍存在若干需考虑的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter mitral valve implantation (TMVI) is still in its infancy and is mainly limited to valve-in-valve or valve-in-ring implantations. We present the early experience with TMVI for severe calcified native MV stenosis. METHODS: Between January 2014 and June 2015, 6 of 11 patients screened (mean age, 77.4 ± 6.3 years; 66% men) with severe native mitral valve (MV) stenosis (mean gradient [Pmean], 11.1 ± 2.1 mm Hg; mean effective orifice area [EOA], 0.9 ± 0.12 cm2) underwent transcatheter MV replacement at our institution as a bailout procedure. Conventional surgical procedures were denied in all patients because of severe annular calcification and extensive comorbidities (mean logistic EuroScore, 31.4% ± 8.3%). The Edwards SAPIEN 3 (29 mm) (Edwards Lifesciences, Irvine, CA) was used in all cases. Procedural access was transapical in 5 cases and concomitant to aortic valve replacement through the left atrium through a sternotomy in 1 case. RESULTS: Initial implantation was successful in 100% of the cases. Because of early migration, 1 patient needed a valve-in-valve procedure. Postoperative echocardiography showed no residual mitral regurgitation in 4 cases (66%) and mild regurgitation in 2 cases (34%). Mean gradients were reduced to 4.2 ± 0.6 mm Hg (mean EOA, 2.8 ± 0.4 cm2). No patient had a stroke during hospitalization, and 30-day mortality was seen in 1 patient (17%) resulting from pneumonia. CONCLUSIONS: TMV implantation using the SAPIEN 3 aortic prosthesis in patients with heavy annular calcification is feasible and represents a reasonable bailout option for inoperable patients. However, several limitations need to be considered in this special patient population.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kiefer P, Noack T, Seeburger J, et al. Transapical Mitral Valve Implantation for Native Mitral Valve Stenosis Using a Balloon-Expandable Prosthesis. Ann Thorac Surg. 2017. PMID: 28760473. doi:10.1016/j.athoracsur.2017.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。